Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
THE EUROASPIRE surveys, which began their first collections of data in 1995-96, are now part of the ESC’s EURObservational Research Programme, or EORP. The programme has grown from just two pilot surveys (both in heart failure) to a broad-ranging and far-reaching programme of 12 registries arranged within the categories of ‘General’, ‘Sentinel’, ‘Special’ and ‘Prevention’, the last of which now includes both arms, hospital and primary care, of the EUROASPIRE data collection.
The latest results from the secondary prevention hospital arm of EUROASPIRE IV were published in February and showed yet again that the large majority of coronary patients in Europe are failing to achieve their lifestyle, risk factor and therapeutic targets as set out in the latest prevention guidelines. This, from the very start of the EORP programme, was one of its fundamental aims - to monitor adherence to guidelines.
And later today EUROASPIRE investigators will present their latest findings on how we are managing cardiovascular risk factors in primary care. ‘Adherence to guidelines is still poor,’ says Chair of the EUROASPIRE Steering Committee Kornelia Kotseva from the National Heart and Lung Institute at Imperial College London. ‘We clearly need to find better ways to manage and control risk factors.’
EUROASPIRE III, published in 2010, interviewed more than 4300 individuals considered at high risk of CVD but without any obvious coronary or atherosclerotic disease. The interviews, performed in 66 general practices in 12 countries, indicated that 16.9% smoked cigarettes, 43.5% had a BMI ≥30 kg/m2, 70.8% had blood pressure ≥140/90 mmHg (≥130/80 in people with diabetes mellitus), 66.4% had total cholesterol ≥5.0 mmol/l (≥4.5 mmol/l in people with diabetes) and 30.2% reported a history of diabetes. Risk factor control was described as ‘very poor’, and the lifestyle of those interviewed - representing a broad population of high risk individuals - as ‘a major cause of concern with persistent smoking and high prevalence of both obesity and central obesity’.
It is the management of these lifestyle factors which the investigators now define as the ‘new challenges’ of this morning’s Symposium. ‘We need a more comprehensive and integrated approach to lifestyle management,’ says Kotseva, ‘because what we’re doing now is clearly not working.
The primary care arm of the latest EUROASPIRE survey was carried out in 2014-2015 in 14 countries (Bosnia & Herzegovina, Bulgaria, Croatia, Kazakhstan, Lithuania, Poland, Portugal, Romania, Russian Federation, Serbia, Spain, Sweden, Ukraine, UK), which included six countries from EUROASPIRE III. Again, the aim was to determine adherence to European guidelines and if preventive cardiology practice in high-risk patients has improved over time.
In each participating general practice, consecutive patients under 80 years without a history of coronary or other atherosclerotic disease were identified by anti-hypertensive and/or lipid lowering and/or anti-diabetes treatments and invited for interview and examination. Primary outcomes are the proportions of patients achieving the lifestyle, blood pressure, lipid and diabetes targets as defined in the 2012 guidelines for CVD prevention. Results will be presented for the first time in this morning’s Symposium, while the time trends (from EUROASPIRE III and IV), will be presented on Tuesday in the ‘Registry III – Prevention’ session.
Following their EUROASPIRE IV report in February on coronary patients in Europe the investigators called for ‘a new approach to cardiovascular prevention...which integrates cardiac rehabilitation and secondary prevention into modern preventive cardiology programmes’. Such recommendations, it now seems, will be just as relevant in primary care as in cardiac rehabilitation. ‘Despite the existence of clear, evidence-based guidelines,’ says Kotseva, ‘their implementation into everyday practice is still disappointing. We need to invest in prevention.’How are we managing cardiovascular risk in the primary care environment? EUROASPIRE IV survey, 30 Aug 11:00-12.30 Bratislava - Village 2
Clinical reality of primary prevention in people at high cardiovascular risk in Europe: a comparison of EUROASPIRE III and IV surveys in general practice, 1 Sep 11.15-11.30 Hyde Park - The Hub
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2015ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.
© 2017 European Society of Cardiology. All rights reserved